FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3202990183> ?p ?o ?g. }

• W3202990183 endingPage "100239" @default.
• W3202990183 startingPage "100239" @default.
• W3202990183 abstract "MET amplification is an important genetic alteration in NSCLC. Unlike in patients with EGFR and ALK alterations, the efficacy of immune checkpoint inhibitors in patients with MET-amplified NSCLC remains unknown.An exploratory analysis of a prospective, multi-institutional cohort comprising 200 patients with advanced or recurrent NSCLC treated with nivolumab monotherapy was performed, and MET amplification was defined as a MET-to-CEP7 ratio of greater than or equal to 2 using fluorescent in situ hybridization. High-level and low-level MET gains were also defined as MET signals ≥10/nuclei and 10> MET signals ≥5/nuclei, respectively. Overall response rates (ORRs) and survival outcomes were evaluated on the basis of the MET gene copy number status.Among 175 patients eligible for analysis, MET amplification was detected in 13 tumors (7.4%). Four (2.3%) high-level and 14 (8.0%) low-level MET gains were also detected. There were no considerable differences in ORRs in accordance with the MET gene copy number status. Similarly, no significant differences in both progression-free survival (PFS) and overall survival (OS) were observed between patients with and without MET-amplified NSCLC (log-rank, p = 0.813 for PFS, and p = 0.855 for OS). Among 101 adenocarcinomas, ORRs in patients with high-level and low-level MET gains (50.0% for both, p = 0.049) were significantly higher than those without MET gains (17.6%), yet survival outcomes for both PFS and OS did not improve.MET amplification was not associated with greater benefit of nivolumab treatment in patients with NSCLC. Further studies are warranted to prioritize immune checkpoint inhibitors in the treatment regimen for patients with MET amplification." @default.
• W3202990183 created "2021-10-11" @default.
• W3202990183 creator A5000381347 @default.
• W3202990183 creator A5000601994 @default.
• W3202990183 creator A5001305867 @default.
• W3202990183 creator A5005542616 @default.
• W3202990183 creator A5030944398 @default.
• W3202990183 creator A5047800281 @default.
• W3202990183 creator A5058136322 @default.
• W3202990183 creator A5063464017 @default.
• W3202990183 creator A5064877798 @default.
• W3202990183 creator A5066306626 @default.
• W3202990183 creator A5075912069 @default.
• W3202990183 creator A5081986737 @default.
• W3202990183 creator A5084998721 @default.
• W3202990183 date "2021-11-01" @default.
• W3202990183 modified "2023-10-05" @default.
• W3202990183 title "MET Amplification and Efficacy of Nivolumab in Patients With NSCLC" @default.
• W3202990183 cites W1773771017 @default.
• W3202990183 cites W1994912526 @default.
• W3202990183 cites W2025288154 @default.
• W3202990183 cites W2026805792 @default.
• W3202990183 cites W2039123767 @default.
• W3202990183 cites W2154149901 @default.
• W3202990183 cites W2154402764 @default.
• W3202990183 cites W2158040154 @default.
• W3202990183 cites W2160725767 @default.
• W3202990183 cites W2171136968 @default.
• W3202990183 cites W2263188953 @default.
• W3202990183 cites W2272081149 @default.
• W3202990183 cites W2293537500 @default.
• W3202990183 cites W2409552123 @default.
• W3202990183 cites W2439107762 @default.
• W3202990183 cites W2466657922 @default.
• W3202990183 cites W2467854262 @default.
• W3202990183 cites W2544185683 @default.
• W3202990183 cites W2561459036 @default.
• W3202990183 cites W2562169753 @default.
• W3202990183 cites W2587950538 @default.
• W3202990183 cites W2591943527 @default.
• W3202990183 cites W2611823218 @default.
• W3202990183 cites W2777461561 @default.
• W3202990183 cites W2792961879 @default.
• W3202990183 cites W2794306956 @default.
• W3202990183 cites W2889307896 @default.
• W3202990183 cites W2894066036 @default.
• W3202990183 cites W2898359687 @default.
• W3202990183 cites W2901062444 @default.
• W3202990183 cites W2911912934 @default.
• W3202990183 cites W2924289105 @default.
• W3202990183 cites W2936661866 @default.
• W3202990183 cites W2944860885 @default.
• W3202990183 cites W2946166987 @default.
• W3202990183 cites W2948399628 @default.
• W3202990183 cites W2949398488 @default.
• W3202990183 cites W2995123342 @default.
• W3202990183 cites W2999414916 @default.
• W3202990183 cites W3015534076 @default.
• W3202990183 cites W3029971508 @default.
• W3202990183 cites W3030625436 @default.
• W3202990183 cites W3031018272 @default.
• W3202990183 cites W3082015854 @default.
• W3202990183 cites W3087519478 @default.
• W3202990183 cites W3113250245 @default.
• W3202990183 cites W3128342266 @default.
• W3202990183 cites W3133838590 @default.
• W3202990183 cites W3167086976 @default.
• W3202990183 cites W3195109303 @default.
• W3202990183 doi "https://doi.org/10.1016/j.jtocrr.2021.100239" @default.
• W3202990183 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/8569583" @default.
• W3202990183 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34766065" @default.
• W3202990183 hasPublicationYear "2021" @default.
• W3202990183 type Work @default.
• W3202990183 sameAs 3202990183 @default.
• W3202990183 citedByCount "3" @default.
• W3202990183 countsByYear W32029901832022 @default.
• W3202990183 countsByYear W32029901832023 @default.
• W3202990183 crossrefType "journal-article" @default.
• W3202990183 hasAuthorship W3202990183A5000381347 @default.
• W3202990183 hasAuthorship W3202990183A5000601994 @default.
• W3202990183 hasAuthorship W3202990183A5001305867 @default.
• W3202990183 hasAuthorship W3202990183A5005542616 @default.
• W3202990183 hasAuthorship W3202990183A5030944398 @default.
• W3202990183 hasAuthorship W3202990183A5047800281 @default.
• W3202990183 hasAuthorship W3202990183A5058136322 @default.
• W3202990183 hasAuthorship W3202990183A5063464017 @default.
• W3202990183 hasAuthorship W3202990183A5064877798 @default.
• W3202990183 hasAuthorship W3202990183A5066306626 @default.
• W3202990183 hasAuthorship W3202990183A5075912069 @default.
• W3202990183 hasAuthorship W3202990183A5081986737 @default.
• W3202990183 hasAuthorship W3202990183A5084998721 @default.
• W3202990183 hasBestOaLocation W32029901831 @default.
• W3202990183 hasConcept C104317684 @default.
• W3202990183 hasConcept C121608353 @default.
• W3202990183 hasConcept C126322002 @default.
• W3202990183 hasConcept C143998085 @default.
• W3202990183 hasConcept C2777542201 @default.
• W3202990183 hasConcept C2777701055 @default.

• next